Insulet's Good Quarter, Lower Bar: The 2027 Reset Is the Story
A 19.6% growth quarter, a 490bp margin beat — and the first explicit admission that the patch-pump moat is no longer absolute
PODD · Earnings Call · 2026-11-04
Insulet's Good Quarter, Lower Bar: The 2027 Reset Is the Story
Insulet's third quarter was strong by almost any operating measure: revenue of $842 million rose 19.2% reported and 19.6% constant currency; adjusted gross margin reached 74.2%, up 200 basis points; adjusted operating margin hit 22%, up 490 basis points; and adjusted EPS of $1.99 rose 60%. U.S. Omnipod grew 14.7%, international grew 33% constant currency, and the global customer base was up more than 20%. Management even narrowed full-year 2026 revenue growth to the top end of its prior range, at 21% to 22% for the total company.
The beat came with a reset
The call's center of gravity, though, was 2027. CFO Flavia Pease gave the preliminary view plainly:
...we would expect the growth next year or to guide next year to be modestly below mid teens which was the framework we provided in the second quarter.
For a company closing its 11th consecutive year of 20%+ growth, that is a meaningful change in slope. The U.S. is now expected to guide toward the low end of the prior 9% to 14% framework, and international growth is expected to moderate meaningfully after a year in which OUS revenue grew north of 35%. The stock has already done the de-rating: PODD sits 53% below its September 2025 peak of $352.82, though it is up 8.4% over the last 90 days and within 3.3% of its recent high. This is not a broken story; it is a de-rated growth story searching for a new base.
The Type 2 action plan: green shoots, not a harvest
The Type 2 problem is no longer a surprise; it is a grind. On the prior call, CEO Ashley McEvoy was direct about the miss: “...we should have understood some of these type 2 trends sooner and done a better job of adapting our commercial and customer service model...” — Ashley McEvoy, President and Chief Executive Officer · 2026-08-05 Three months later the update is better but still qualitative: “we did see green shoots. We saw improvement, modest improvement in our T2 retention trends.” — Ashley A. McEvoy, President and Chief Executive Officer · 2026-11-04
Management still will not put a number on the Type 2 attrition rate. Asked whether the 25% to 30% range the Street has triangulated was fair, the answer circled back to stable Type 1 retention and "modest" Type 2 gains. That is the tell: the KPI the market actually wants remains a black box. The company's own keyword set has migrated accordingly. Last quarter's top phrase was Type 2 community; this quarter's top themes are action plan, green shoots and a deliberately conservative approach to guidance. That is what a growth narrative sounds like when it becomes a remediation narrative. Omnipod Discover — now adopted by more than 35,000 users and 5,000 clinicians — is the most credible fix, and the retention specialists, revised sampling governance and sales compensation tied to Type 2 retention are all sensible. But all of it is "building over time," which is management's way of saying: not yet in the numbers.
The moat gets a number: a couple of share points
For two years, management's competitive answer was category expansion — new entrants grow the pie rather than take share. In May: “...this is not a market share trading. This is about bringing new people into the category and the category expanding as a whole.” — Ashley McEvoy, President and Chief Executive Officer · 2026-05-06 On this call the language changed: “we are gonna lose a couple share points as competitors come in.” — Ashley A. McEvoy, President and Chief Executive Officer · 2026-11-04 That is the most important sentence in the transcript. It is not a collapse — Insulet still expects to lead new customer starts in a AID market where it has driven roughly two-thirds of category growth — but the share point concession is explicit, and it lands in the same breath as a more measured market-growth assumption. OmniPod 6, with its second and final 510(k) submitted and a 2027 launch planned alongside the first simultaneous U.S./OUS rollout in company history, is the answer. The timing matters: the innovation arrives just as the competitive noise builds.
Access is steadier. One of three 2027 PBM contracts is finalized with the remaining two expected within weeks, and management reiterated stable pricing: “Overall, we think in The United States, it will be stable pricing.” — Ashley A. McEvoy, President and Chief Executive Officer · 2026-11-04 Reassuring, but stable pricing is not pricing power — and the Street will want contract terms, not philosophy.
The math and the tape
The fundamentals confirm the operating-leverage story was real. In the June quarter, total revenue was $802 million, up 24% year over year, with gross margin at 70.2% — consistent with the 74.2% adjusted print this quarter. Yet free cash flow less stock-based compensation collapsed to $36 million, down 79%, as capex rose 75%. The call cites $212 million of year-to-date free cash flow and a full-year target near $275 million, so cash is not broken — but the company is funding capacity and working capital while simultaneously announcing a $1 billion buyback authorization, $400 million of which is planned for the fourth quarter. At a $10.7 billion market cap that is roughly 3.7% of the company in one quarter: meaningful, and a genuine signal of confidence, but not enough to settle the growth debate on its own.
Valuation has already done much of the work. Price to revenue is 3.5x, down 63% year over year and a fraction of the 18.9x peak in 2021. Operating margin, meanwhile, has genuinely climbed — operating margin has expanded by roughly 31 points across the last three years of the series. The de-rating discounts a slowdown; the open question is whether 2027 guidance is conservatively set or merely the first cut.
Bottom line
Q3 was a beat; the report is a reset. Insulet is trading near its recent high after a 53% drawdown, and management just told investors to expect slower growth, a couple of lost share points, and a more contested automated insulin delivery market — while the fully closed loop for type 2 diabetes that could re-open the primary-care funnel does not arrive until 2028. If Type 2 retention builds and Omnipod 6 lands on time, the lowered 2027 bar becomes a launchpad. If not, the debate becomes whether Insulet is still a 20% grower at all. The tape says investors want to believe the first scenario; the transcript says management is hedging toward the second.